TuisGLAXO ⢠NSE
add
GlaxoSmithKline Pharmaceuticals Ltd
Vorige sluiting
ā¹2Ā 517,30
Dagwisseling
ā¹2Ā 450,80 - ā¹2Ā 529,90
Jaarwisseling
ā¹2Ā 220,30 - ā¹3Ā 515,70
Markkapitalisasie
428,67Ā mjd INR
Gemiddelde volume
69,19Ā k
P/V-verhouding
41,97
Dividend-opbrengs
1,66%
PrimĆŖre beurs
NSE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (INR) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 10,41Ā mjd | 9,67% |
Bedryfskoste | 3,26Ā mjd | 2,93% |
Netto inkomste | 2,96Ā mjd | 28,60% |
Netto winsgrens | 28,39 | 17,27% |
Wins per aandeel | ā | ā |
EBITDA | 3,61Ā mjd | 27,20% |
Effektiewe belastingkoers | 26,08% | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (INR) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 20,61Ā mjd | -2,36% |
Totale bates | ā | ā |
Totale aanspreeklikheid | ā | ā |
Totale ekwiteit | 17,08Ā mjd | ā |
Uitstaande aandele | 169,41Ā m | ā |
Prys om te bespreek | 24,97 | ā |
Opbrengs op bates | ā | ā |
Opbrengs op kapitaal | 50,34% | ā |
Kontantvloei
Netto kontantverandering
| (INR) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 2,96Ā mjd | 28,60% |
Kontant van bedrywe | ā | ā |
Kontant van beleggings | ā | ā |
Kontant van finansiering | ā | ā |
Netto kontantverandering | ā | ā |
Beskikbare kontantvloei | ā | ā |
Meer oor
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Gestig
13 Nov. 1924
Hoofkwartier
Webwerf
Werknemers
3Ā 113